European Cancer Patient Coalition

CAR-T White Paper Online Launch Event

Theme: Future consideration for CAR-T therapies: A multi-stakeholder perspective

Thursday 28 November 2022

14h00 - 15h00 CET online

Context:

Cancer is a leading cause of death worldwide with increasing incidence and mortality. Over the years, several conventional treatments have been developed and for decades, therapy relied on the conventional surgery, chemotherapy, and radiotherapy. However, the effectiveness of such approaches remains limited, especially to patients with refractory or relapsed diseases. Hence, there is an ongoing search for therapies with improved outcomes, one of them is immunotherapy, such as Chimeric Antigen Receptor T-cells (CAR-T), which enhances the patient's immune response capacity. These are treatments used for severe diseases associated with considerable societal costs and can offer sustained disease remission and even cure for some patients with relapsed or refractory disease, which have otherwise limited options and poor prognosis.

CAR-T is an EMA and FDA approved cell therapy for the treatment of certain blood cancers and the approval was based on a ground-breaking clinical study reporting 83% complete remission after only three months of CAR-T treatment in patients, who had received many unsuccessful rounds of traditional blood cancer therapy.

In view of the foregoing, the ECPC white paper aims to bring to light the information available on the current situation of CAR-T therapies in term of accessibility, delivery, pricing, reimbursement, as well as ethics

Objectives:

Even though CAR-Ts offer enormous promise, they also come with considerable scientific, clinical, logistical, policy and regulatory challenges. The main objective of this session is to introduce CAR-T modality among relevant stakeholders and to explore its potential benefits for cancer patients across EU states. In addition, to critically consider the challenges in its' acceptability, affordability, availably and implementation and the approaches that could be employed to achieve an optimal cross-border pay-off matrix across Europe.

Moderator: Charis Girvalaki - ECPC Director

Program Agenda			
1.	14:00 -14:05	Introduction and welcome (*setting the scene*)	**Charis Girvalaki**, ECPC Director
2.	14:05 - 14:15	EU regulations and Frameworks on CAR-T	**MEP Cristian Busoi**
3.	14:15 - 14:25	Accessibility, affordability of CAR-T treatment in Europe	**Professor Nicola Normanno,** ECPC Scientific Committee Member
4.	14:25-14:35	Bioethics around CAR-T treatment	**Professor Ulrich Jäger,** Professor of Haematology University of Vienna and member of European Affairs European, Haematology Association (EHA)
5.	14:35-14:45	The healthcare professional's perspective	**Professor Kostas Stamatopoulos,** ECPC Scientific Committee Member and Haematology specialist.
6.	14:45 - 14:55	Patient perspective on CAR-T	**Jana Pelouchova**, ECPC Vice President
7.	14:55 - 15:00	Q & A moderated by Charis Girvalaki, ECPC Director	**Audience and Panellists**